NM
Publicaties op Oncologisch.com
CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AM...
Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML.
Behandeling Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and ...
Augmented RIC versus standaard RIC voor allo-SCT bij AML: BMT CTN 0901